Sophie Wildsmith

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Robert L. Ferris, Robert I. Haddad, Caroline Even et al. · Annals of Oncology · 2020 · 365 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

Lillian L. Siu, Caroline Even, Éva Remenár et al. · JAMA Oncology · 2018 · 310 citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

Bradley J. Monk, Takafumi Toita, Xiaohua Wu et al. · The Lancet Oncology · 2023 · 204 citations

Medicine, Oncology, Pharmacotherapy +12

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

Amanda Psyrri, Jérôme Fayette, Kevin J. Harrington et al. · Annals of Oncology · 2022 · 144 citations · Full text

Medicine, Immunology, Oncology +17